Holen Sie sich die Stockscreener-App
12.80
4.48%
-0.60
Handel nachbörslich:
12.95
0.15
+1.17%
Ars Pharmaceuticals Inc Aktie (SPRY) Neueste Nachrichten
How the (SPRY) price action is used to our Advantage - news.stocktradersdaily.com
High Insider Ownership Growth Stocks To Know In April 2025 - simplywall.st
Revenues Not Telling The Story For ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) After Shares Rise 28% - simplywall.st
ARS Pharmaceuticals, Inc. (SPRY) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings - ACCESS Newswire
Downgrade: Here's How Analysts See ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Performing In The Near Term - simplywall.st
ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Analysts Are Reducing Their Forecasts For This Year - Yahoo Finance
Long Term Trading Analysis for (SPRY) - Stock Traders Daily
ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Q4 2024 Earnings Call Transcript - MSN
Raymond James lifts ARS Pharmaceuticals price target to $32 - Investing.com
ARS Pharmaceuticals: Strategic Growth and Market Penetration Justify Buy Rating - TipRanks
ARS Pharmaceuticals outlines 2025 growth strategy with neffy commercialization and global expansion - MSN
Neffy 1 mg Approved to Treat Severe Allergic Reactions in Younger Children - Pulmonology Advisor
ARS Pharmaceuticals’ Earnings Call Highlights Growth and Challenges - MSN
Ars pharmaceuticals chief commercial officer Eric Karas sells $140,000 in stock - Investing.com Australia
Ars pharmaceuticals chief commercial officer Eric Karas sells $140,000 in stock By Investing.com - Investing.com South Africa
neffy From ARS Pharmaceuticals, Inc - Pharmacy Times
ARS Pharmaceuticals Full Year 2024 Earnings: Beats Expectations - Yahoo Finance
ARS Pharmaceuticals, Inc. (SPRY) Q4 Earnings and Revenues Beat Estimates - MSN
Decoding ARS Pharmaceuticals Inc (SPRY): A Strategic SWOT Insigh - GuruFocus
ARS Pharmaceuticals Reports Strong 2024 Financial Results - TipRanks
Raymond James maintains $28 target on ARS Pharma stock By Investing.com - Investing.com South Africa
ARS Pharmaceuticals: Surging On Solid EarningsBut Real Challenges Await (NASDAQ:SPRY) - Seeking Alpha
Raymond James maintains $28 target on ARS Pharma stock - Investing.com India
ARS Pharma Retakes Its 50-Day Line In Bullish Post-Earnings Move. Here's Why. - MSN
Earnings call transcript: ARS Pharmaceuticals Q4 2024 earnings beat expectations - Investing.com
ARS Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates - GlobeNewswire
ARS Pharmaceuticals Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Sector Update: Health Care Stocks Decline Pre-Bell Thursday - TradingView
Sector Update: Health Care - TradingView
ARS Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2024 - Marketscreener.com
ARS Pharmaceuticals Reports Q4 Results, Swings to 2024 Earnings -March 20, 2025 at 07:45 am EDT - MarketScreener
ARS PHARMACEUTICALS Earnings Results: $SPRY Reports Quarterly Earnings - Nasdaq
Earnings Flash (SPRY) ARS Pharmaceuticals Posts Q4 Revenue $86.6M -March 20, 2025 at 07:13 am EDT - Marketscreener.com
Earnings Flash (SPRY) ARS Pharmaceuticals Posts Q4 EPS $0.48, vs. FactSet Est of $-0.04 Loss - Marketscreener.com
ARS Pharmaceuticals, Inc. SEC 10-K Report - TradingView
ARS Pharma Crushes Q4 with $49.9M Profit as Neffy Launch Gains Momentum - StockTitan
ARS Pharmaceuticals Inc (SPRY) Q4 2024 Earnings Call Highlights: Strong Financial Position and ... By GuruFocus - Investing.com Canada
This company’s epinephrine nasal spray reverses allergic reactions—no needle required - Fast Company
From cancer vaccines to COPD treatments, these 10 companies are developing innovative medicines - Fast Company
(SPRY) Investment Report - news.stocktradersdaily.com
Steward Partners Investment Advisory LLC Raises Position in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) - Defense World
ARS Pharmaceuticals (SPRY) to Release Quarterly Earnings on Thursday - Defense World
Scotiabank Begins Coverage on ARS Pharmaceuticals (NASDAQ:SPRY) - Defense World
Scotiabank Initiates Coverage of ARS Pharmaceuticals (SPRY) with Sector Outperform Recommendation - Nasdaq
Rhumbline Advisers Buys 1,824 Shares of ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) - Defense World
ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Given Consensus Recommendation of “Buy” by Brokerages - Defense World
Ars pharmaceuticals director Laura Shawver sells $560,445 in stock By Investing.com - Investing.com Canada
US FDA expands use of ARS Pharma's allergic reaction nasal spray in 15-30 kg patients - Reuters
San Diego biotech gets FDA approval for EpiPen alternative for kids - MSN
Exploring High Growth Tech Stocks in the US Market - Simply Wall St
California biotech company gets FDA approval for EpiPen alternative for kids - East Bay Times
10.70%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):